Table 2 Multiple linear regression with Willingness to Pay (WTP) ranging from $0 to $500,000
Regression Key covariates | Multiple Linear Regression Estimates of Incremental Net Benefit [SE] (p-value) | ||||||
|---|---|---|---|---|---|---|---|
NB($0) (amount by which benefits outweigh costs, when an extra QALY is worth $0) | NB($50 k) (amount by which benefits outweigh costs, when an extra QALY is worth $50,000) | NB($100 k) (amount by which benefits outweigh costs, when an extra QALY is worth $100,000) | NB($200 k) (amount by which benefits outweigh costs, when an extra QALY is worth $200,000) | NB($300 k) (amount by which benefits outweigh costs, when an extra QALY is worth $300,000) | NB($400 k) (amount by which benefits outweigh costs, when an extra QALY is worth $400,000) | NB($500 k) (amount by which benefits outweigh costs, when an extra QALY is worth $500,000) | |
cetuximab TX indicator | −14,185 [2409] (< 0.0001) | −14,042 [2667] (< 0.0001) | − 13,899 [4403] (0.0017) | − 13,612 [8766] (0.1214) | − 13,326 [13,348] (0.3188) | − 13,040 [17,982] (0.4688) | −12,754 [22,637] (0.5735) |
KRAS-WT | 1210 [2289] (0.5975) | 2458 [2534] (0.3327) | 3707 [4184] (0.3763) | 6204 [8329] (0.4569) | 8701 [12,683] (0.4932) | 11,198 [17,086] (0.5127) | 13,695 [21,509] (0.5248) |
cetuximab TX × KRAS-WT | − 16,238 [3165] (< 0.0001) | − 8488 [3505] (0.0160) | −738 [5787] (0.8986) | 14,762 [11,520] (0.2009) | 30,262 [17,541] (0.0854) | 45,762 [23,631] (0.0536) | 61,262 [29,747] (0.0402) |
Overall INB estimate of cetuximab for KRAS-WT patients, $ | −30,422 | −22,530 | − 14,637 | 1149 | 16,935 | 32,721 | 48,507 |